Paper Details

  1. Home
  2. Paper Details

Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer.

Author: BogaertsJ, GallantG, GatzemeierU, GottfriedM, HarperP, LucentiA, MattsonK, RobinetG, SalvatiF, de MarinisF, ten VeldeG P, von PawelJ

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The combination of paclitaxel and cisplatin showed a better clinical response, with a 9% improvement in overall response rate and a longer time to progression compared to high-dose cisplatin alone in patients with advanced NSCLC. However, the combination did not show a significant improvement in survival.
Paper Details　
Original Abstract of the Article :
PURPOSE: New effective chemotherapy is needed to improve the outcome of patients with advanced non-small-cell lung cancer (NSCLC). Paclitaxel administered as a single agent or in combination with cisplatin has been shown to be a potentially new useful agent for the treatment of NSCLC. PATIENTS AND ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.2000.18.19.3390

データ提供：米国国立医学図書館（NLM）

High-Dose Cisplatin vs. Paclitaxel/Cisplatin: A Desert Duel in Lung Cancer Treatment

Dr. Camel here, exploring the challenging terrain of lung cancer, a disease that can feel like navigating a suffocating desert of illness. This research, like a fierce desert duel, compares the effectiveness of two chemotherapy regimens: high-dose cisplatin and a combination of paclitaxel and cisplatin, in treating patients with advanced non-small-cell lung cancer (NSCLC).

A Battle for Survival

The researchers, like seasoned desert warriors, conducted a large randomized phase III trial to determine which chemotherapy regimen offered the best chance of survival for patients with advanced NSCLC. They found that the paclitaxel/cisplatin combination produced a better clinical response, resulting in a longer time to progression. However, neither regimen was able to significantly improve overall survival. This is like two powerful desert warriors battling fiercely, but ultimately neither able to claim complete victory.

Finding the Right Weapon

This research highlights the importance of carefully considering different treatment options for lung cancer, finding the right weapon to combat this challenging disease. It's like choosing the best path through a treacherous desert, selecting the route that offers the highest chance of survival. The study emphasizes the need for personalized treatment approaches, taking into account the individual needs and characteristics of each patient.

Dr. Camel's Conclusion

This research is a valuable contribution to the ongoing fight against lung cancer, offering insights into the effectiveness of different chemotherapy regimens. It's like a battle map in the desert, guiding us towards more effective treatments for this challenging disease. This study underscores the need for ongoing research and development, seeking innovative strategies to combat lung cancer and improve outcomes for patients.

Date :
  1. Date Completed 2000-10-25
  2. Date Revised 2022-03-17
Further Info :

Pubmed ID

11013280

DOI: Digital Object Identifier

10.1200/JCO.2000.18.19.3390

Related Literature

Article Analysis
・Effective treatment of lung cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.